NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
Clinical Trials
5 trialsNCT04017546 2024-09-19
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS
Cyclacel Pharmaceuticals, Inc.
Phase 1 Completed
NCT02552953 2024-05-31
A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers
Cyclacel Pharmaceuticals, Inc.
Phase 1 Completed
NCT05168904 2024-02-08
A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)
Cyclacel Pharmaceuticals, Inc.
Phase 1/2 Suspended
NCT03739554 2024-01-25
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL
Cyclacel Pharmaceuticals, Inc.
Phase 1 Completed